泓博医药
(301230)
| 流通市值：26.76亿 | | | 总市值：48.59亿 |
| 流通股本：7686.03万 | | | 总股本：1.40亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 352,738,072.83 | 169,429,129.41 | 544,471,262.04 | 391,402,290.83 |
| 营业收入 | 352,738,072.83 | 169,429,129.41 | 544,471,262.04 | 391,402,290.83 |
| 二、营业总成本 | 329,746,732.17 | 157,965,262.18 | 553,727,749.83 | 396,611,989.68 |
| 营业成本 | 254,215,060.6 | 121,329,610.64 | 414,537,085.85 | 298,418,994.94 |
| 税金及附加 | 1,279,704.26 | 738,073.61 | 1,764,306.01 | 1,254,150.81 |
| 销售费用 | 7,127,402.06 | 3,624,165.13 | 13,898,744.71 | 9,644,308.83 |
| 管理费用 | 46,704,457.86 | 23,146,216.58 | 75,283,356.16 | 49,076,054.68 |
| 研发费用 | 18,996,372.04 | 8,726,167.99 | 47,260,968.85 | 35,900,683.08 |
| 财务费用 | 1,423,735.35 | 401,028.23 | 983,288.25 | 2,317,797.34 |
| 其中:利息费用 | 4,270,293.62 | 2,172,427.41 | 9,281,930.57 | 7,046,648.79 |
| 其中:利息收入 | 1,037,136.55 | 459,725.36 | 3,131,004.31 | 2,635,926.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,313,005.94 | 1,771,230.16 | 4,971,768.04 | 3,999,617.46 |
| 加:投资收益 | 105,380.53 | 59,178.08 | 3,435,499.97 | 3,503,429.13 |
| 资产减值损失(新) | -1,802,460.95 | -1,007,845.9 | 649,767.33 | 2,282,890.76 |
| 信用减值损失(新) | -3,357,088.65 | -1,782,650.81 | -1,293,577.94 | -1,315,054.1 |
| 其他收益 | 1,494,474 | 615,660.33 | 5,126,046.59 | 3,172,132.72 |
| 四、营业利润 | 22,744,651.53 | 11,119,439.09 | 3,633,016.2 | 6,433,317.12 |
| 加:营业外收入 | 13,351.44 | 1.44 | 189,118.24 | 156,953.35 |
| 减:营业外支出 | 80,830.06 | 59,654.59 | 287,018.07 | 125,083.32 |
| 五、利润总额 | 22,677,172.91 | 11,059,785.94 | 3,535,116.37 | 6,465,187.15 |
| 减:所得税费用 | -2,084,253.36 | -914,087.88 | -13,548,038.46 | -8,778,418.7 |
| 六、净利润 | 24,761,426.27 | 11,973,873.82 | 17,083,154.83 | 15,243,605.85 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 24,761,426.27 | 11,973,873.82 | 17,083,154.83 | 15,243,605.85 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 24,761,426.27 | 11,973,873.82 | 17,083,154.83 | 15,243,605.85 |
| 扣除非经常损益后的净利润 | 20,159,213.2 | 9,683,298.46 | 4,957,358.15 | 6,111,053.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | 0.09 | 0.12 | 0.11 |
| (二)稀释每股收益 | 0.18 | 0.09 | 0.12 | 0.11 |
| 八、其他综合收益 | -112,334.74 | -81,158.69 | 64,923.15 | -4,824.99 |
| 归属于母公司股东的其他综合收益 | -112,334.74 | -81,158.69 | 64,923.15 | -4,824.99 |
| 九、综合收益总额 | 24,649,091.53 | 11,892,715.13 | 17,148,077.98 | 15,238,780.86 |
| 归属于母公司股东的综合收益总额 | 24,649,091.53 | 11,892,715.13 | 17,148,077.98 | 15,238,780.86 |
| 公告日期 | 2025-08-28 | 2025-04-29 | 2025-04-24 | 2024-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |